Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma

Gastroenterology

Volumn 153, Issue 5, 2017, Pages 1429-1443.e5

  Xie, Yangchun ^a,b,c   Zhu, Shan ^a   Zhong, Meizuo ^b   Yang, Manhua ^b,c   Sun, Xiaofan ^a   Liu, Jinbao ^a   Kroemer, Guido ^{d,e,f,g,h,i,j}   Lotze, Michael ^c   Zeh, Herbert J ^c   Kang, Rui ^c   Tang, Daolin ^a,c  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

^f INSERM   (France)

^g SORBONNE UNIVERSITÉ   (France)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Antitumor Immunity; ATP; HMGB1; Regulated Cell Death

Indexed keywords

AURORA A KINASE; AURORA KINASE INHIBITOR; CCT 137690; GLYCOGEN SYNTHASE KINASE 3BETA; UNCLASSIFIED DRUG; 3-((4-(6-BROMO-2-(4-(4-METHYLPIPERAZIN-1-YL)PHENYL)-3H-IMIDAZO(4,5-B)PYRIDIN-7-YL)PIPERAZIN-1-YL)METHYL)-5-METHYLISOXAZOLE; ANTINEOPLASTIC AGENT; AURKA PROTEIN, HUMAN; AURKA PROTEIN, MOUSE; IMIDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BXPC-3 CELL LINE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL DEATH; CELL MEMBRANE; CELL VACUOLE; CELL VOLUME; CFPAC-1 CELL LINE; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DISEASE ASSOCIATION; DRUG IDENTIFICATION; DRUG SCREENING; ENZYME INHIBITION; GENE EXPRESSION; GENOME ANALYSIS; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; MIA PACA-2 CELL LINE; MOUSE; NECROPTOSIS; NONHUMAN; PANC-1 CELL LINE; PANC02 CELL LINE; PANC2.03 CELL LINE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREATIC DUCTAL CARCINOMA CELL LINE; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NECROSIS; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TIME FACTOR; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AURORA KINASE A; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; IMIDAZOLES; MICE, NUDE; MICE, TRANSGENIC; NECROSIS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; SIGNAL TRANSDUCTION; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85032739924     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.07.036     Document Type: Article

References (43)

1. Von Hoff, D.D., Ervin, T., Arena, F.P., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369 (2013), 1691–1703.
2. Conroy, T., Desseigne, F., Ychou, M., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 (2011), 1817–1825.
3. Weinlich, R., Oberst, A., Beere, H.M., et al. Necroptosis in development, inflammation and disease. Nat Rev Mol Cell Biol 18 (2017), 127–136.
4. Galluzzi, L., Kepp, O., Chan, F.K., et al. Necroptosis: mechanisms and relevance to disease. Annu Rev Pathol 12 (2017), 103–130.
5. Pasparakis, M., Vandenabeele, P., Necroptosis and its role in inflammation. Nature 517 (2015), 311–320.
6. Seifert, L., Miller, G., Molecular pathways: the necrosome—a target for cancer therapy. Clin Cancer Res 23 (2017), 1132–1136.
7. Bavetsias, V., Linardopoulos, S., Aurora kinase inhibitors: current status and outlook. Front Oncol, 5, 2015, 278.
8. Torres, M.P., Rachagani, S., Souchek, J.J., et al. Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy. PLoS One, 8, 2013, e80580.
9. Kang, R., Xie, Y., Zhang, Q., et al. Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Cell Res 27 (2017), 916–932.
10. Glienke, W., Maute, L., Wicht, J., et al. The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines. Tumour Biol 33 (2012), 757–765.
11. Ochiai, T., Saito, Y., Saitoh, T., et al. Inhibition of IkappaB kinase beta restrains oncogenic proliferation of pancreatic cancer cells. J Med Dent Sci 55 (2008), 49–59.
12. Jani, J.P., Arcari, J., Bernardo, V., et al. PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol Cancer Ther 9 (2010), 883–894.
13. Arbitrario, J.P., Belmont, B.J., Evanchik, M.J., et al. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol 65 (2010), 707–717.
14. Galluzzi, L., Buque, A., Kepp, O., et al. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 17 (2017), 97–111.
15. Tang, D., Kang, R., Coyne, C.B., et al. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev 249 (2012), 158–175.
16. Yang, H., Ma, Y., Chen, G., et al. Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. Oncoimmunology, 5, 2016, e1149673.
17. Fu, J., Bian, M., Jiang, Q., et al. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 5 (2007), 1–10.
18. Faisal, A., Vaughan, L., Bavetsias, V., et al. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Mol Cancer Ther 10 (2011), 2115–2123.
19. Bavetsias, V., Large, J.M., Sun, C., et al. Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. J Med Chem 53 (2010), 5213–5228.
20. Wu, X., Liu, W., Cao, Q., et al. Inhibition of Aurora B by CCT137690 sensitizes colorectal cells to radiotherapy. J Exp Clin Cancer Res, 33, 2014, 13.
21. Crosio, C., Fimia, G.M., Loury, R., et al. Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol 22 (2002), 874–885.
22. Cheong, J.W., Jung, H.I., Eom, J.I., et al. Aurora-A kinase inhibition enhances the cytosine arabinoside-induced cell death in leukemia cells through apoptosis and mitotic catastrophe. Cancer Lett 297 (2010), 171–181.
23. Lu, Y., Liu, Y., Jiang, J., et al. Knocking down the expression of Aurora-A gene inhibits cell proliferation and induces G2/M phase arrest in human small cell lung cancer cells. Oncol Rep 32 (2014), 243–249.
24. Zhang, H., Chen, X., Liu, B., et al. Effects of stable knockdown of Aurora kinase A on proliferation, migration, chromosomal instability, and expression of focal adhesion kinase and matrix metalloproteinase-2 in HEp-2 cells. Mol Cell Biochem 357 (2011), 95–106.
25. Ling, Y.H., el-Naggar, A.K., Priebe, W., et al. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol 49 (1996), 832–841.
26. Li, Z., Liu, W., Mo, B., et al. Caffeine overcomes genistein-induced G2/M cell cycle arrest in breast cancer cells. Nutr Cancer 60 (2008), 382–388.
27. Nikonova, A.S., Astsaturov, I., Serebriiskii, I.G., et al. Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci 70 (2013), 661–687.
28. Dar, A.A., Belkhiri, A., El-Rifai, W., The aurora kinase A regulates GSK-3beta in gastric cancer cells. Oncogene 28 (2009), 866–875.
29. Yoshino, Y., Ishioka, C., Inhibition of glycogen synthase kinase-3 beta induces apoptosis and mitotic catastrophe by disrupting centrosome regulation in cancer cells. Sci Rep, 5, 2015, 13249.
30. Hingorani, S.R., Petricoin, E.F., Maitra, A., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4 (2003), 437–450.
31. Su, Z., Yang, Z., Xie, L., et al. Cancer therapy in the necroptosis era. Cell Death Differ 23 (2016), 748–756.
32. Kelly, K.R., Ecsedy, J., Mahalingam, D., et al. Targeting aurora kinases in cancer treatment. Curr Drug Targets 12 (2011), 2067–2078.
33. Carvajal, R.D., Tse, A., Schwartz, G.K., Aurora kinases: new targets for cancer therapy. Clin Cancer Res 12 (2006), 6869–6875.
34. Li, D., Zhu, J., Firozi, P.F., et al. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 9 (2003), 991–997.
35. Katayama, H., Wang, J., Treekitkarnmongkol, W., et al. Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73. Cancer Cell 21 (2012), 196–211.
36. Zou, Z., Yuan, Z., Zhang, Q., et al. Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells. Autophagy 8 (2012), 1798–1810.
37. Wang, H., Sun, L., Su, L., et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell 54 (2014), 133–146.
38. Dondelinger, Y., Declercq, W., Montessuit, S., et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep 7 (2014), 971–981.
39. Jacobs, K.M., Bhave, S.R., Ferraro, D.J., et al. GSK-3beta: a bifunctional role in cell death pathways. Int J Cell Biol, 2012, 2012, 930710.
40. Liu, P., Xu, B., Shen, W., et al. Dysregulation of TNFalpha-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1. Leukemia 26 (2012), 1293–1300.
41. Xia, Z., Wei, P., Zhang, H., et al. AURKA governs self-renewal capacity in glioma-initiating cells via stabilization/activation of beta-catenin/Wnt signaling. Mol Cancer Res 11 (2013), 1101–1111.
42. Grassilli, E., Narloch, R., Federzoni, E., et al. Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy. Clin Cancer Res 19 (2013), 3820–3831.
43. Seifert, L., Werba, G., Tiwari, S., et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Nature 532 (2016), 245–249.